The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Transferrin/transferrin receptor‐mediated drug delivery
Abstract
Since transferrin was discovered more than half a century ago, a considerable effort has been made towards understanding tranferrin‐mediated iron uptake. However, it was not until recently with the identification and characterization of several new genes related to iron homeostasis, such as the hemochromatosis protein HFE and the iron transporter DMT1, that our knowledge has been advanced dramatically. A major pathway for cellular iron uptake is through internalization of the complex of iron‐bound transferrin and the transferrin receptor, which is negatively modulated by HFE, a protein related to hereditary hemochromatosis. Iron is released from transferrin as the result of the acidic pH in endosome and then is transported to the cytosol by DMT1. The iron is then utilized as a cofactor by heme and ribonucleotide reductase or stored in ferritin. Apart from iron, many other metal ions of therapeutic and diagnostic interests can also bind to transferrin at the iron sites and their transferrin complexes can be recognized by many cells. Therefore, transferrin has been thought as a “delivery system” for many beneficial and harmful metal ions into the cells. Transferrin has also be widely applied as a targeting ligand in the active targeting of anticancer agents, proteins, and genes to primary proliferating malignant cells that overexpress transferrin receptors. This is achieved by conjugation of transferrin with drugs, proteins, hybride systems with marcomolecules and as liposomal‐coated systems. Conjugates of anticancer drugs with transferrin can significantly improve the selectivity and toxicity and overcome drug resistance, thereby leading to a better treatment. The coupling of DNA to transferrin via a polycation such as polylysine or via cationic liposomes can target and transfer of the extrogenous DNA particularly into proliferating cells through receptor‐mediated endocytosis. These kinds of non‐viral vectors are potential alternatives to viral vectors for gene therapy, if the transfection efficiency can be improved. Moreover, transferrin receptors have shown potentials in delivery of therapeutic drugs or genes into the brain across blood–brain barrier. © 2002 Wiley Periodicals, Inc. Med Res Rev, 22, No. 3, 225–250, 2002; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/med.10008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Cloning and characterization of a mammalian proton-coupled metal-ion transporter
Gunshin, H., Mackenzie, B., Berger, U. V., Gunshin, Y., Romero, M. F., Boron, W. F., Nussberger, S., Gollan, J. L., & Hediger, M. A. (1997) · Nature · doi:10.1038/41343 · Cited by 3,166 · cited 1×
“Our knowledge concerning cellular iron transport has been markedly advanced by the recent discoveries of several genes such as HFE,(96) associated with hereditary hemochromatosis, and divalent metal transporter (DMT1/Nramp2), a membrane iron transporter.(97,98) Those proteins are likely to play an important role in th…”
BackgroundAndrews, N. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412607 · Cited by 2,130
THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
Endicott, J. A., & Ling, V. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.001033 · Cited by 2,071
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4407 · Cited by 1,575
Hentze, M. W., & Kühn, L. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8175 · Cited by 1,292
pH and the recycling of transferrin during receptor-mediated endocytosis.
Dautry-Varsat, A., Ciechanover, A., & Lodish, H. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.8.2258 · Cited by 1,179
Ogris, M., Brunner, S., Schüller, S., Kircheis, R., & Wagner, E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300900 · Cited by 1,178
Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene
Fleming, M. D., Trenor, C. C., Su, M. A., Foernzler, D., Beier, D. R., Dietrich, W. F., & Andrews, N. C. (1997) · Nature Genetics · doi:10.1038/ng0897-383 · Cited by 1,159 · cited 1×
“Our knowledge concerning cellular iron transport has been markedly advanced by the recent discoveries of several genes such as HFE,(96) associated with hereditary hemochromatosis, and divalent metal transporter (DMT1/Nramp2), a membrane iron transporter.(97,98) Those proteins are likely to play an important role in th…”
Background
Cited by
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Advanced materials and processing for drug delivery: The past and the future
Zhang, Y., Chan, H. F., & Leong, K. W. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.003 · Cited by 1,000
New metal complexes as potential therapeutics
Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 946
Targeted delivery of low molecular drugs using chitosan and its derivatives
Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.003 · Cited by 821
Transferrin and transferrin receptors update
Kawabata, H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.037 · Cited by 692
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 634
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Transferrin: structure, function and potential therapeutic actions
Gomme, P. T., McCann, K. B., & Bertolini, J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03333-1 · Cited by 480
More Effective Nanomedicines through Particle Design
Wang, J., Byrne, J. D., Napier, M. E., & DeSimone, J. M. (2011) · Small · doi:10.1002/smll.201100442 · Cited by 466
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals
Ying, X., Wen, H., Lu, W.-L., Du, J., Guo, J., Tian, W., Men, Y., Zhang, Y., Li, R.-J., Yang, T.-Y., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.020 · Cited by 447
Clinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 375
Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356
Wang, J., Tian, S., Petros, R. A., Napier, M. E., & DeSimone, J. M. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1043177 · Cited by 330
Sahoo, S. K., Ma, W., & Labhasetwar, V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327
Huang, R.-Q., Qu, Y.-H., Ke, W.-L., Zhu, J.-H., Pei, Y.-Y., & Jiang, C. (2007) · The FASEB Journal · doi:10.1096/fj.06-7380com · Cited by 311
Li, Y., He, H., Jia, X., Lu, W.-L., Lou, J., & Wei, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.004 · Cited by 310
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors
He, H., Li, Y., Jia, X.-R., Du, J., Ying, X., Lu, W.-L., Lou, J.-N., & Wei, Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.002 · Cited by 303
Organelle targeting: third level of drug targeting
Padh, H., & Sakhrani, N. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s45614 · Cited by 269
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
The rat blood-brain barrier transcriptome
Enerson, B. E., & Drewes, L. R. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600249 · Cited by 205
Liposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198
“50 Fishman et al demonstrated that Tf could cross the BBB via receptor-mediated endocytosis, 51 and more recent studies have shown that liposomes modified with Tf can also penetrate the BBB in vitro.”
Nakase, I., Lai, H., Singh, N. P., & Sasaki, T. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.09.003 · Cited by 190
Jones, D. T., Trowbridge, I. S., & Harris, A. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3857 · Cited by 75
Zhao, H., Bao, X.-J., Wang, R.-Z., Li, G.-L., Gao, J., Ma, S.-H., Wei, J.-J., Feng, M., Zhao, Y.-J., Ma, W.-B., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.111 · Cited by 73
Metadata
- Authors
- Li, H., & Qian, Z. M.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2002-03-26
- Volume
- 22
- Issue
- 3
- Pages
- 225-250
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3099031341
- Cited by
- 441
- References
- 195
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.